Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- EP-Mint to Acquire Sogo SMO: EPS
November 2, 2009
- Lawmakers to Have Stronger Influence on Medical Fees
November 2, 2009
- BioWa Licenses POTELLIGENT Technology to NKTT
November 2, 2009
- 3 JMA Top Management Team Members Not Reappointed as Chuikyo Members
November 2, 2009
- Sanofi-aventis Licenses New Anti-Diabetic Agent from Wellstat Pharmaceuticals
November 2, 2009
- Price Maintenance System Essential to Make Drug Market in Japan More Attractive: Mr Kinosita
November 2, 2009
- 35 Products Approved Including Januvia/Glactiv -1-
November 2, 2009
- Korosho Increases FY2010 Budget Request to ¥28,889.4 Bil.
November 2, 2009
- Generics Use Rate by Far the Highest in Okinawa Prefecture
November 2, 2009
- Nat'l Univ. Hospitals Plans to Start Joint Purchasing in FY2010
October 26, 2009
- Hokkaido Univ. Hospital to Increase Direct Purchase of Drugs
October 26, 2009
- Cravit Remains No. 1 on Both HP, GP Markets: Rep Track Survey
October 26, 2009
- Korosho to Base Requirements for Premium for Generics on Their Volume Dispensed
October 26, 2009
- Otsuka Holdings Receives 2009 Investor in France Award
October 26, 2009
- New Gov't Will Continue to Promote Use of Generics: Mr Isobe
October 26, 2009
- Global Pharmaceutical Market to Grow 4-6% in 2010: IMS Health
October 26, 2009
- Biosimilars to Save 8.1 Billion Euro by 2020 in Germany
October 26, 2009
- BUSINESS NEWS IN BRIEF
October 26, 2009
- Sales of OTC Drugs Increase in Aug. for the First Time in 3 Months: Crecon
October 26, 2009
- Korosho to Stop Use of Add'l ¥85.4 Bil. in FY2009 Supplementary Budget
October 26, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…